Tracking Immune Activation by Stress Proteins In Vivo
体内应激蛋白追踪免疫激活
基本信息
- 批准号:7183492
- 负责人:
- 金额:$ 25.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-03-01 至 2010-01-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressAdjuvantAdjuvanticityAdoptive TransferAffectAmino AcidsAnimal ModelAntigensBindingBiologyCD8-Positive T-LymphocytesCD8B1 geneCell CommunicationCell Surface ReceptorsCell SurvivalCellsChickensChimeric ProteinsDataDendritic CellsDopachrome isomeraseEmployee StrikesEventFlow CytometryFluorochromeFrequenciesGenerationsGoalsHeat shock proteinsHourImmuneImmune responseImmune systemImmunizationKineticsLifeLinkLongevityMaintenanceMeasuresMediatingMemoryMonoclonal AntibodiesMusMycobacterium tuberculosisNumbersPeptidesPhenotypeProductionProliferatingProteinsReportingResearch PersonnelSignal TransductionStress-Induced ProteinSystemT memory cellT-Cell ActivationT-LymphocyteTestingTimeTransgenic OrganismsTumor ImmunityVaccinesViralbasecancer therapycell typecytokinedaydensityin vivoinsightlymph nodesmelanocytenovelprogramsreceptorresearch studyresponsestress proteinuptakevaccine development
项目摘要
DESCRIPTION (provided by applicant): Vaccines containing peptides linked to stress proteins are the most potent known T cell immunogens. However, the precise mechanisms by which they activate immune cells remain unclear. To address this, we will track activated dendritic cells (DCs) and CD8+ T cells in mice immunized with antigens fused to the stress protein hsp70, and determine which cytokines and cell surface receptors are required for their responses. Our preliminary studies reveal hspTO fusion vaccines elicit much more potent and durable specific CD8+ T cell responses than antigen alone or with other adjuvants. Our underlying hypothesis is that antigen/hsp70 fusions are potent vaccines because they stimulate DCs to provide an optimal microenvironment for CD8+ T cell activation. This microenvironment is defined by high antigen density and strong costimulation. To test this, we will track in vivo DC and CD8+ T cell responses in draining lymph nodes, and the resultant effector and memory CD8+ T lymphocytes in the periphery. Novel aspects of our proposal include: 1) quantifying the amount of antigen presented by activated DCs, 2) the effect hsp70 fusion proteins have on DC lifespan, 3) determining which of the several reported hsp70-receptors are necessary or sufficient for delivering activation signals to DCs in vivo, and 4) determining the costimulatory and cytokines required for the profound effect our vaccine has CD8+ T cell memory. The results of these experiments will allow us to manipulate stress protein-induced responses rationally with the ultimate goal of maximizing their use for cancer therapy.
描述(由申请人提供):含有与应力蛋白相关的肽的疫苗是最有效的已知T细胞免疫原子。但是,它们激活免疫细胞的确切机制尚不清楚。为了解决这个问题,我们将跟踪活化的树突状细胞(DCS)和CD8+ T细胞,用融合到应激蛋白HSP70的抗原免疫的小鼠中,并确定其反应需要哪些细胞因子和细胞表面受体。我们的初步研究表明,HSPTO融合疫苗比单独或与其他佐剂相比,引起更有效和耐用的特异性CD8+ T细胞反应。我们的基本假设是抗原/HSP70融合是有效的疫苗,因为它们刺激DC为CD8+ T细胞激活提供最佳的微环境。这种微环境由高抗原密度和强烈的共刺激来定义。为了测试这一点,我们将在排水淋巴结中跟踪体内DC和CD8+ T细胞反应,以及所得的效应子和周围的记忆CD8+ T淋巴细胞。 Novel aspects of our proposal include: 1) quantifying the amount of antigen presented by activated DCs, 2) the effect hsp70 fusion proteins have on DC lifespan, 3) determining which of the several reported hsp70-receptors are necessary or sufficient for delivering activation signals to DCs in vivo, and 4) determining the costimulatory and cytokines required for the profound effect our vaccine has CD8+ T cell 记忆。这些实验的结果将使我们能够合理地操纵应激蛋白诱导的反应,以最大程度地提高其用于癌症治疗的最终目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHRISTOPHER A PENNELL其他文献
CHRISTOPHER A PENNELL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHRISTOPHER A PENNELL', 18)}}的其他基金
Unraveling the Pathophysiology of Neurotoxicity Induced by CAR T-cells
揭示 CAR T 细胞引起的神经毒性的病理生理学
- 批准号:
10678939 - 财政年份:2022
- 资助金额:
$ 25.25万 - 项目类别:
Unraveling the Pathophysiology of Neurotoxicity Induced by CAR T-cells
揭示 CAR T 细胞引起的神经毒性的病理生理学
- 批准号:
10453491 - 财政年份:2022
- 资助金额:
$ 25.25万 - 项目类别:
Tracking Immune Activation by Stress Proteins In Vivo
体内应激蛋白追踪免疫激活
- 批准号:
7541420 - 财政年份:2006
- 资助金额:
$ 25.25万 - 项目类别:
Tracking Immune Activation by Stress Proteins In Vivo
体内应激蛋白追踪免疫激活
- 批准号:
7036312 - 财政年份:2006
- 资助金额:
$ 25.25万 - 项目类别:
Tracking Immune Activation by Stress Proteins In Vivo
体内应激蛋白追踪免疫激活
- 批准号:
7341718 - 财政年份:2006
- 资助金额:
$ 25.25万 - 项目类别:
GENETICALLY OPTIMIZED IMMUNOTOXINS FOR LEUKEMIA THERAPY
用于白血病治疗的基因优化免疫毒素
- 批准号:
6626710 - 财政年份:2001
- 资助金额:
$ 25.25万 - 项目类别:
GENETICALLY OPTIMIZED IMMUNOTOXINS FOR LEUKEMIA THERAPY
用于白血病治疗的基因优化免疫毒素
- 批准号:
6489315 - 财政年份:2001
- 资助金额:
$ 25.25万 - 项目类别:
GENETICALLY OPTIMIZED IMMUNOTOXINS FOR LEUKEMIA THERAPY
用于白血病治疗的基因优化免疫毒素
- 批准号:
6263185 - 财政年份:2001
- 资助金额:
$ 25.25万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Prostate Specific Anti-androgen Therapy for Localized Prostate Cancer
前列腺特异性抗雄激素疗法治疗局限性前列腺癌
- 批准号:
10760194 - 财政年份:2023
- 资助金额:
$ 25.25万 - 项目类别:
Regulatory Mechanisms Addressing Diabetic Vasculopathy
解决糖尿病血管病变的调节机制
- 批准号:
10718850 - 财政年份:2023
- 资助金额:
$ 25.25万 - 项目类别:
Low cost, Broad Spectrum Cancer Vaccine Targeting Human Papillomavirus
针对人乳头瘤病毒的低成本、广谱癌症疫苗
- 批准号:
10650067 - 财政年份:2022
- 资助金额:
$ 25.25万 - 项目类别:
Methods for generalizing inferences from cluster randomized controlled trials to target populations
将整群随机对照试验的推论推广到目标人群的方法
- 批准号:
10362886 - 财政年份:2022
- 资助金额:
$ 25.25万 - 项目类别:
Brain Networks of Turning Performance with Aging and Stroke
衰老和中风影响转向性能的大脑网络
- 批准号:
10536898 - 财政年份:2022
- 资助金额:
$ 25.25万 - 项目类别: